BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Stake Raised by Hsbc Holdings PLC

Hsbc Holdings PLC increased its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 32.7% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 125,004 shares of the biotechnology company’s stock after buying an additional 30,788 shares during the quarter. Hsbc Holdings PLC owned about 0.06% of BioCryst Pharmaceuticals worth $759,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the business. CWM LLC grew its stake in shares of BioCryst Pharmaceuticals by 200.0% in the second quarter. CWM LLC now owns 5,658 shares of the biotechnology company’s stock worth $35,000 after purchasing an additional 3,772 shares in the last quarter. Signaturefd LLC grew its position in BioCryst Pharmaceuticals by 560.5% in the 2nd quarter. Signaturefd LLC now owns 6,598 shares of the biotechnology company’s stock valued at $41,000 after buying an additional 5,599 shares in the last quarter. Quarry LP bought a new stake in shares of BioCryst Pharmaceuticals during the 4th quarter worth about $54,000. Seven Eight Capital LP acquired a new stake in shares of BioCryst Pharmaceuticals in the 1st quarter worth approximately $57,000. Finally, Natixis boosted its holdings in shares of BioCryst Pharmaceuticals by 400.6% in the first quarter. Natixis now owns 11,684 shares of the biotechnology company’s stock valued at $59,000 after acquiring an additional 9,350 shares in the last quarter. 85.88% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on BCRX shares. Barclays upped their target price on BioCryst Pharmaceuticals from $6.00 to $7.00 and gave the stock an “equal weight” rating in a research report on Tuesday, August 6th. StockNews.com raised BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, August 6th. HC Wainwright reiterated a “buy” rating and issued a $30.00 price target on shares of BioCryst Pharmaceuticals in a research report on Tuesday, August 6th. Royal Bank of Canada restated an “outperform” rating and set a $10.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Tuesday, August 6th. Finally, JMP Securities lifted their price objective on shares of BioCryst Pharmaceuticals from $15.00 to $16.00 and gave the stock a “market outperform” rating in a research note on Tuesday, August 6th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, BioCryst Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $14.17.

BioCryst Pharmaceuticals Trading Up 0.5 %

Shares of BCRX opened at $7.62 on Monday. BioCryst Pharmaceuticals, Inc. has a 1-year low of $4.03 and a 1-year high of $8.88. The stock has a market capitalization of $1.57 billion, a P/E ratio of -7.12 and a beta of 1.88. The business’s 50-day moving average price is $7.83 and its 200 day moving average price is $6.45.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings results on Monday, August 5th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.11. The firm had revenue of $109.30 million for the quarter, compared to analyst estimates of $98.30 million. During the same quarter in the prior year, the firm earned ($0.24) EPS. The firm’s revenue was up 34.9% compared to the same quarter last year. On average, research analysts predict that BioCryst Pharmaceuticals, Inc. will post -0.38 earnings per share for the current year.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.